Recently, with progress in antibody or protein engineering technology, different types of BsAbs based on novel strategies are at various stages of development and clinical stage. BsAbs come in many formats, from relatively small proteins to large immunoglobulin G (IgG)-like molecules with additional domains attached. The complexity of the novel structure also posts challenges in CMC area such as expression, purification, and product stability.

This webinar presents bi-specific antibody CMC strategies including cell line development, upstream process development, downstream process development, and analytical method development. Optimized strategies help to break bottlenecks in bi-specific antibody CMC area and provide faster and better IND-enabling services.